News

TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
Trodelvy (sacituzumab govitecan-hziy) is a prescription infusion that treats certain forms of breast cancer in adults. Learn about dosage, side effects, and more.
Trodelvy is a prescription drug used to treat certain breast and bladder cancers. Learn about the drug's uses, success rate, effectiveness, and more.
Trodelvy is a first-in-class Trop-2-directed antibody-drug conjugate. The ASCENT-03 study is a global, open-label, randomized phase III trial evaluating the efficacy and safety of Trodelvy ...
Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The phase 3 ASCENT ...
Trodelvy (sacituzumab govitecan-hziy) is a brand-name IV infusion prescribed for certain types of breast cancer in adults. As with other drugs, Trodelvy can cause side effects, such as diarrhea ...
Trodelvy, in combination with Merck's immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new results.
Trodelvy plus Keytruda significantly improves progression-free survival in metastatic triple-negative breast cancer expressing PD-L1 compared to Keytruda and chemotherapy. The safety profile of the ...
Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer ...
Trodelvy when given in combination with Keytruda resulted in a median progression-free survival (PFS) of 11.2 months. FOSTER CITY, Calif., May 31, 2025--Gilead Sciences, Inc. ...